Approval · Notice of Compliance 29157 · 2022
SUMMIT ULTRA: Notice of Compliance 29157
Issued October 7, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29157
- Date
- October 7, 2022
- Company
- Pendopharm Division Of Pharmascience IncMontreal, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the inner & outer labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUMMIT ULTRA | 02360357 | Dormant |
Medicinal ingredients
- IBUPROFEN 400 MG per TAB
- METHOCARBAMOL 500 MG per TAB